{"filings":[{"id":92859,"accession_number":"0001437402-26-000021","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Ardelyx Q1 revenue $93.4M (+38% YoY); IBSRELA revenue $70.1M (+58% YoY)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $37.6M ($0.15/sh) vs $41.1M ($0.17/sh) Q1 2025; share-based comp $14.2M.","Cash & investments $238.1M as of Mar 31, 2026; reiterated FY 2026 IBSRELA guidance $410-430M.","IBSRELA Phase 3 CIC trial (ACCEL) enrolling; topline data expected H2 2027.","Appointed Rajani Dinavahi, M.D. as CMO and Felecia Ettenberg, Esq. as CLO in April.","Refinanced debt with SLR Investment Corp for better terms; Morgan Stanley advised."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":94473000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104048,"accession_number":"0001437402-26-000012","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Ardelyx reports 2025 revenue $407.3M; IBSRELA up 73% to $274.2M; guides 2026 higher","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["IBSRELA revenue $274.2M in 2025 (+73% YoY); Q4 $86.6M (+61% YoY).","XPHOZAH revenue $103.6M in 2025; 2026 guidance $110-120M.","Total 2025 revenue $407.3M; net loss $61.6M ($0.26 loss per share).","Cash $264.7M at Dec 31, 2025; fully capitalised for current plans.","Phase 3 ACCEL trial for tenapanor in CIC dosed first patient; topline H2 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":407320000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104047,"accession_number":"0001437402-26-000003","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Ardelyx reports preliminary Q4 2025 IBSRELA sales ~$87M, XPHOZAH ~$28M; cash $265M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary unaudited U.S. net product sales: IBSRELA ~$87M Q4, ~$274M FY 2025.","Preliminary unaudited U.S. net product sales: XPHOZAH ~$28M Q4, ~$104M FY 2025.","Cash, cash equivalents and short-term investments ~$265M as of Dec 31, 2025, unaudited.","All figures are preliminary and subject to adjustment upon final audited results."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":407320000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120330,"accession_number":"0001437402-25-000021","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Ardelyx CLO and CMO resign effective Dec 31; interim CMO appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Elizabeth Grammer resigns as Chief Legal and Administrative Officer effective Dec 31, 2025; will serve as General Counsel then Senior Advisor for 24 months.","Edward Conner resigns as CMO effective Dec 31, 2025 for personal reasons; Dr. Laura Williams appointed interim CMO.","Grammer transition agreement: retains base salary, target bonus 45% for 2025, no ongoing bonus as advisor; equity continues vesting.","Laura Williams, former CMO and current Chief Patient Officer, serves as interim CMO until permanent hire."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120329,"accession_number":"0001437402-25-000016","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ardelyx Q3 2025: product revenue $105.5M, IBSRELA +92% YoY, guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q3 product revenue $105.5M (+15% YoY); net loss $1.0M ($0.00 per share).","IBSRELA revenue $78.2M (+92% YoY, +20% QoQ); 2025 guidance raised to $270-275M.","XPHOZAH revenue $27.4M (+9% QoQ); YoY decline due to loss of Part D coverage.","Cash $242.7M; new NHE3 inhibitor RDX10531 with IND submission targeted for 2026.","Appointed Sue Hohenleitner as CFO effective Nov 4, plus new CMO and CTO in Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":282105000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120328,"accession_number":"0001437402-25-000008","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Ardelyx appoints Sue Hohenleitner as CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Sue Hohenleitner as CFO effective Nov 4, 2025; she joins Oct 13, 2025.","Hohenleitner previously VP & CFO of J&J Innovative Medicine NA ($36B business).","Annual base salary $550,000, target bonus 45% of base, sign-on bonus $180,000.","Received option to purchase 578,104 shares at $5.01/share and 146,896 RSUs, four-year vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136907,"accession_number":"0001628280-25-037441","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["2.02","5.02","5.03","9.01"],"status":"ready","headline":"Ardelyx Q2 revenue $97.7M (+33%), raises IBSRELA guidance; CFO to depart","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $97.7M (+33% YoY); IBSRELA net sales $65M (+84% YoY); XPHOZAH net sales $25M (-33% YoY).","Raised FY2025 IBSRELA U.S. net sales revenue outlook to $250-260M from prior guidance.","Net loss $19.1M ($0.08/sh) vs $16.5M ($0.07) YoY; cash & investments $238.5M at June 30, 2025.","CFO Justin Renz to transition out by Dec 31, 2025 or upon new CFO start; transition agreement signed.","Drew $48.7M net from SLR term loan; option to draw additional $100M in two tranches."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":171776000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136906,"accession_number":"0001628280-25-034132","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Ardelyx draws $50M term loan, secures $100M additional capacity from SLR","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Immediate draw of $50.0M (Term E Loan) under Fifth Amendment to 2022 Loan Agreement.","Option to draw $100.0M in two $50.0M tranches (Term F & G), available through June 2026 and Dec 2026.","Term E interest: 4.00% + 1-month SOFR (floor 4.70%); Incremental loans: 4.95% + SOFR (floor 3.50%).","Term E and existing loans mature July 1, 2028; Incremental loans mature July 1, 2030; interest-only periods.","Company paid $250K funding fee on Term E and $1.0M facility fee on Incremental loan commitments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154150,"accession_number":"0001628280-25-032172","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Ardelyx shareholders approve equity plan amendment increasing share reserve by 10M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved first amendment to 2014 equity plan, raising authorized shares from 58.5M to 68.5M.","David Mott (92.1M for) and Michael Raab (101.2M for) elected as Class II directors.","Say-on-pay proposal approved with ~91% of votes cast in favor (131.3M for).","Ratification of Ernst & Young as independent auditor for FY2025 approved (182.5M for).","Approximately 187.2M shares voted out of 239.3M outstanding; broker non-votes were 44.1M on most proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154149,"accession_number":"0001628280-25-021514","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ardelyx reports Q1 2025 total revenue $74.1M (+61% YoY); IBSRELA $44.4M, XPHOZAH $23.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $74.1M (+61% YoY); net loss $41.1M ($0.17 loss per share) vs $26.5M loss in Q1 2024.","IBSRELA net product sales $44.4M (+57% YoY); FY2025 guidance reaffirmed at $240–250M.","XPHOZAH net product sales $23.4M (+30% ex-returns reserve); $5.0M milestone from Fosun for China tenapanor approval.","Cash $214.0M (Dec 2024: $250.1M); SG&A $83.2M, R&D $14.9M.","Appointed Merdad Parsey to Board and Laura Williams as Chief Patient Officer in April 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":74114000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154148,"accession_number":"0001628280-25-020477","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Ardelyx appoints Merdad Parsey to Board of Directors, effective April 28, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Merdad Parsey, M.D., Ph.D., appointed as Class I director, effective April 28, 2025.","Also appointed to Nominating and Corporate Governance Committee effective June 18, 2025.","Initial equity compensation: option and RSUs each valued at ~$225,000, plus annual cash retainers of $50k (board) and $5k (committee).","Dr. Parsey is independent per Nasdaq Listing Rule 5605."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172753,"accession_number":"0001628280-25-006564","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ardelyx reports FY2024 revenue $333.6M; narrows net loss to $39.1M; provides 2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $333.6M in 2024, up from $124.5M in 2023; driven by IBSRELA ($158.3M) and XPHOZAH ($160.9M) sales.","Net loss narrowed to $39.1M ($0.17 per share) from $66.1M ($0.30 per share) in 2023.","Cash and investments ended at $250.1M; drew $49.7M under term loan in Q4 2024.","IBSRELA 2025 net sales guidance: $240–250M; reaffirmed peak combined sales potential of $1.75B.","SG&A expenses rose to $258.7M from $134.4M due to sales team expansion and XPHOZAH launch."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":333615000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172752,"accession_number":"0001628280-25-001246","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Ardelyx reports preliminary Q4 2024 net product sales: IBSRELA $54M, XPHOZAH $57M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["IBSRELA net product sales: ~$54M in Q4 2024, ~$158M full year.","XPHOZAH net product sales: ~$57M in Q4 2024, ~$161M full year.","Cash, cash equivalents, and short-term investments: ~$250M as of Dec 31, 2024 (unaudited)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":333615000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189774,"accession_number":"0001628280-24-048258","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Ardelyx appoints Joseph Reilly as Principal Accounting Officer effective Nov 15, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joseph Reilly, age 51, appointed Principal Accounting Officer, replacing Robert Felsch.","Reilly previously SVP Finance at Ardelyx; spent 15+ years at Bristol Myers Squibb and a decade at EY.","Felsch remains with Ardelyx as a senior financial advisor to ensure smooth transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189773,"accession_number":"0001628280-24-044547","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ardelyx Q3 revenue $98.2M; IBSRELA $40.6M, XPHOZAH $51.5M; net loss $0.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["IBSRELA Q3 net sales $40.6M (+15% QoQ); full-year guidance set at $145-150M.","XPHOZAH Q3 net sales $51.5M (+39% QoQ); strong launch continues.","Total revenue $98.2M (up 74% YoY); net loss $0.8M vs net income $6.6M in Q3 2023.","Cash $190.4M at Sep 30; drew $49.7M from SLR loan (SOFR+4.02%) in October.","Appointed Eric Foster as CCO in August; CMS Part D change for XPHOZAH cited as 2025 headwind."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":217486000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189772,"accession_number":"0001628280-24-042602","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2024-10-09T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Ardelyx signs lease for 15,012 sq ft Newark office; existing Fremont lease amended","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial 39-month term starting ~Feb 10, 2025; one 60-month extension option.","Initial base rent $3.15/sq ft/month ($47,288/month); 3.5% annual escalations.","Sixth amendment extends existing Fremont lease to later of March 10, 2025 or new lease commencement.","Landlord will fund tenant improvements; tenant responsible for change-request costs.","Lease includes $141,863 letter of credit requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206280,"accession_number":"0001628280-24-036749","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Ardelyx enters commercial supply agreement with Catalent for IBSRELA through 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement covers tableting, testing, release and bulk packaging of IBSRELA (tenapanor HCl) at Catalent's Winchester, KY facility.","Initial term through Dec 31, 2028, with automatic renewal for two-year terms thereafter.","Minimum purchase commitment: minimum number of batches per contract year.","Unit pricing adjusted annually starting Jan 1, 2025, based on producer price index.","Either party can terminate for material breach after cure period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206279,"accession_number":"0001628280-24-034110","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ardelyx Q2 total revenue $73.2M, driven by IBSRELA $35.4M and XPHOZAH $37.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["IBSRELA Q2 net sales $35.4M, up ~25% QoQ; XPHOZAH Q2 net sales $37.1M, up from $15.2M in Q1 2024.","Total revenue $73.2M vs $22.3M YoY; net loss narrowed to $16.5M ($0.07/sh) from $17.1M ($0.08/sh) YoY.","FY 2024 IBSRELA revenue guidance unchanged at $140-150M; cash and investments $186M at quarter end.","Filed lawsuit against CMS over ESRD PPS rule threatening XPHOZAH access; declined TDAPA application.","SG&A expenses doubled to $64.7M primarily due to ongoing commercialization of both products."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":119245000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206278,"accession_number":"0001628280-24-030708","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2024-07-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ardelyx opts out of CMS TDAPA for XPHOZAH, foregoing add-on payment","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Ardelyx will not apply to include XPHOZAH (tenapanor) in CMS ESRD PPS TDAPA program.","Decision aimed at preserving patient access to the phosphate absorption inhibitor.","By opting out, XPHOZAH will not receive transitional add-on payment from Medicare.","Announcement made on July 2, 2024; no financial guidance provided on impact.","Company expects to rely on standard ESRD PPS bundled payment for XPHOZAH."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223358,"accession_number":"0001628280-24-028413","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Ardelyx shareholders approve amended equity plans at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment and restatement of 2014 Equity Incentive Award Plan (78.3M for, 46.1M against).","Stockholders approved amendment and restatement of 2014 Employee Stock Purchase Plan (119.8M for, 4.6M against).","Class I directors William Bertrand and Onaiza Cadoret-Manier elected until 2027 (over 100M votes for each).","Non-binding say-on-pay approved (116.2M for, 7.7M against) and Ernst & Young ratified as auditor (167.1M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223357,"accession_number":"0001628280-24-024996","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ardelyx CCO Susan Rodriguez resigns; stays in advisory role through 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Susan Rodriguez resigned as Chief Commercial Officer on May 22, 2024, by mutual agreement with Ardelyx.","She will continue in an advisory capacity through the end of 2024 to support the transition.","No successor has been announced as of the filing date.","Rodriguez's departure is effective immediately but she remains available for consultation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223356,"accession_number":"0001628280-24-019986","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ardelyx Q1 product revenue $45.6M (IBSRELA $28.4M, XPHOZAH $15.2M); net loss $26.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 product-related revenue $45.6M: IBSRELA $28.4M (+149% YoY), XPHOZAH $15.2M (first full quarter after Oct 2023 approval).","Net loss $26.5M ($0.11/sh) vs $26.8M ($0.13/sh) in Q1 2023; cash & investments $202.6M.","Full-year 2024 IBSRELA net sales guidance raised to $140M-$150M.","SG&A expenses $53.0M (+$26.2M YoY) due to commercialization of both products.","Appointed Mike Kelliher as EVP Corporate Development and Strategy in March 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":46023000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}